Avandia and Diabetic Nephropathy
Diabetic nephropathy is considered to be the leading cause of end-stage renal disease. Cardiovascular risks and diabetic nephropathy are known to be closely linked. And the annual cardiovascular death rates are considerably higher in patients with microalbuminuria. Apart from microalbuminuria, other factors that accelerate the progression of diabetic nephropathy to end-stage renal disease include poor glycemic control, high blood pressure, obesity, smoking, and genetic susceptibility.
Microalbuminuria is the first unmistakable symptom of diabetic nephropathy. It can be also a sign of target organ damage. Lowering blood pressure and normalizing glucose levels can reduce microalbuminuria. In this way Avandia containing Rosiglitazone simultaneously reduces the excretion of albumin in the urine or arrests it all together and decreases high blood pressure significantly. Thus, it is of vital importance that Avandia proves capable of reducing urinary albumin excretion in type 2 diabetes.
There is evidence that the active ingredient of Avandia, Rosiglitazone maleate, ameliorates diabetic nephropathy by inhibiting reactive oxygen species.
Diabetic nephropathy is a serious complication, but it should be borne in mind that at its initial stages it is quite possible to reverse this complication on condition a patient keeps healthy eating habits, exercises regular glycemic control and tries to normalize glucose levels. That is why at this stage Avandia can procure a salutary effect on the course of treatment. But if the patient's condition deteriorates and diabetic nephropathy gradually develops into renal impairment, it is recommended to discontinue Avandia and apply to insulin which is easy to use to stabilize glucose levels during the day.
You can order Avandia here. It's fast, cheap and completely anonymous.